US 12,129,469 B2
Modified short interfering nucleic acid (siNA) molecules and uses thereof
Leonid Beigelman, San Mateo, CA (US); Vivek Kumar Rajwanshi, Cupertino, CA (US); Markus Hossbach, Kulmbach (DE); Rajendra K. Pandey, Foster City, CA (US); Jin Hong, Pacifica, CA (US); Laxman Eltepu, San Ramon, CA (US); Saul Martinez Montero, San Bruno, CA (US); and N. Tilani S. De Costa, South San Francisco, CA (US)
Assigned to Aligos Therapeutics, Inc., South San Francisco, CA (US)
Filed by Aligos Therapeutics, Inc., South San Francisco, CA (US)
Filed on Jul. 28, 2023, as Appl. No. 18/361,363.
Application 18/361,363 is a division of application No. 18/059,561, filed on Nov. 29, 2022.
Application 18/059,561 is a division of application No. 17/672,268, filed on Feb. 15, 2022, granted, now 11,549,110.
Application 17/672,268 is a continuation of application No. 17/194,079, filed on Mar. 5, 2021.
Claims priority of provisional application 63/109,196, filed on Nov. 3, 2020.
Claims priority of provisional application 62/986,150, filed on Mar. 6, 2020.
Prior Publication US 2023/0365970 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61P 31/20 (2006.01)
CPC C12N 15/1131 (2013.01) [A61K 31/713 (2013.01); A61K 45/06 (2013.01); A61P 31/20 (2018.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/351 (2013.01); C12N 2320/31 (2013.01)] 30 Claims
 
1. A method of treating hepatitis B virus (HBV) comprising administering to a subject with HBV a double stranded short interfering nucleic acid (siNA) comprising:
(a) a sense strand comprising 19-21 nucleotides in a nucleic acid sequence that is at least 80% identical to SEQ ID NO: 40, wherein 15 or more of the nucleotides are modified nucleotides independently selected from a 2′-O-methyl nucleotide and a 2′-fluoro nucleotide, and wherein at least 11 of the modified nucleotides are a 2′-O-methyl nucleotide and at least 4 of the modified nucleotides are a 2′-fluoro nucleotide; and
(b) an antisense strand comprising 19-21 nucleotides in a nucleic acid sequence that is at least 80% complementary to SEQ ID NO: 40, wherein 15 or more of the nucleotides are modified nucleotides independently selected from a 2′-O-methyl nucleotide and a 2′-fluoro nucleotide, and wherein at least 11 of the modified nucleotides are a 2′-O-methyl nucleotide and 4 to 6 of the modified nucleotides are a 2′-fluoro nucleotide.